Utilization of oral anticoagulants in Korean nonvalvular atrial fibrillation patients

被引:0
作者
Hye-Yoon Song
Kyung-Bok Son
Ju-Young Shin
SeungJin Bae
机构
[1] Ewha Womans University,College of Pharmacy
[2] Sungkyunkwan University,School of Pharmacy
来源
International Journal of Clinical Pharmacy | 2019年 / 41卷
关键词
Anticoagulant; NOAC; Nonvalvular atrial fibrillation; Prescribing; South korea; Vitamin-K antagonist;
D O I
暂无
中图分类号
学科分类号
摘要
Background Although the majority of clinical guidelines indicate the use of NOAC (nonvitamin K antagonist oral anticoagulant) over vitamin K antagonist in nonvalvular atrial fibrillation patients, there is no information on real-world prescription factors that lead to a specific type of oral anticoagulant selection. Objective To evaluate the prescription factors for choosing a specific oral anticoagulant for nonvalvular atrial fibrillation patients in Korea. Setting Nationwide sampled database in South Korea. Methods In this study, we defined nonvalvular atrial fibrillation patients as having one or more hospitalizations or two or more out-patient visits with a stroke risk score (CHA2DS2-VASc scores) ≥ 2 eligible for oral anticoagulant therapy from Jan 1st, 2016 to Dec 31st, 2016. Baseline characteristics were analyzed, including sex, age, comorbidities, CHA2DS2-VASc, bleeding risk score (mHAS-BLED), prescribing specialty, insurance type, medical institution type and location. Univariate and multivariate logistic regression analyses were conducted for being prescribed NOAC compared with vitamin K antagonist. Main outcome measure Adjusted odds ratio of the NOAC group and vitamin K antagonist group. Results Of 9,226 patients eligible for oral anticoagulant therapy, 4999 patients (54.2%) received oral anticoagulant therapy, and 4517 patients took NOAC or vitamin K antagonist only during the study period. Prior stroke, transient ischemic attack, thromboembolism, thyroid disease, dyslipidemia, cancer, mHAS-BLED ≥ 5, in-patient care, and specialty in internal medicine and neurology were positive predictors of NOAC use over vitamin K antagonist, whereas young age (≤64), renal dysfunction, and secondary care institution were negative predictors of NOAC use over vitamin K antagonist. Conclusions The presence of comorbidities was linked to NOAC use over vitamin K antagonist, which is different from prescription factor studies in other countries and requires further study.
引用
收藏
页码:1434 / 1441
页数:7
相关论文
共 148 条
[1]  
Chiang CE(2017)2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation J Arrhythm 33 345-367
[2]  
Okumura K(2007)Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 857-867
[3]  
Zhang S(2000)Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 160 41-46
[4]  
Chao TF(2015)Underutilization of warfarin for stroke prophylaxis in patients with atrial fibrillation or atrial flutter in Korea J Cardiol 66 475-481
[5]  
Siu CW(2016)2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS Eur J Cardiothorac Surg 50 e1-e88
[6]  
Wei Lim T(2018)2018 KHRS guidelines for stroke prevention therapy in Korean patients with nonvalvular atrial fibrillation Korean J Med 93 311-312
[7]  
Hart RG(2018)2018 KHRS guidelines for stroke prevention therapy in korean patients with nonvalvular atrial fibrillation Korean J Med 93 87-109
[8]  
Pearce LA(2018)Impact of the health insurance coverage policy on oral anticoagulant prescription among patients with atrial fibrillation in Korea from 2014 to 2016 J Korean Med Sci 33 e163-231
[9]  
Aguilar MI(2017)Trends in the incidence and prevalence of atrial fibrillation and estimated thromboembolic risk using the CHA2DS2-VASc score in the entire Korean population Int J Cardiol 236 226-174
[10]  
Bungard TJ(2017)Initiation of anticoagulation in atrial fibrillation: which factors are associated with choice of anticoagulant? J Intern Med 282 164-368